Pasar al contenido principal

CCAR2: EN LA ENCRUCIJADA ENTRE LA REPARACION DEL ADN, EL METABOLISMO CELULAR Y LA SEÑALIZACION POR ESTRES

PID2022-136791NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection

  • Ceppi, Ilaria
  • Dello Stritto, Maria Rosaria
  • Mütze, Martin
  • Braunshier, Stefan
  • Mengoli, Valentina
  • Reginato, Giordano
  • Võ, Hồ Mỹ Phúc
  • Jimeno, Sonia
  • Acharya, Ananya
  • Roy, Megha
  • Sanchez, Aurore
  • Halder, Swagata
  • Howard, Sean Michael
  • Guérois, Raphaël
  • Huertas Sánchez, Pablo
  • Noordermeer, Sylvie M.
  • Seidel, Ralf
  • Cejka, Petr
DNA double-strand break (DSB) repair by homologous recombination is initiated by DNA end resection, a process involving the controlled degradation of the 5'-terminated strands at DSB sites1,2. The breast cancer suppressor BRCA1-BARD1 not only promotes resection and homologous recombination, but it also protects DNA upon replication stress1,3-9. BRCA1-BARD1 counteracts the anti-resection and pro-non-homologous end-joining factor 53BP1, but whether it functions in resection directly has been unclear10-16. Using purified recombinant proteins, we show here that BRCA1-BARD1 directly promotes long-range DNA end resection pathways catalysed by the EXO1 or DNA2 nucleases. In the DNA2-dependent pathway, BRCA1-BARD1 stimulates DNA unwinding by the Werner or Bloom helicase. Together with MRE11-RAD50-NBS1 and phosphorylated CtIP, BRCA1-BARD1 forms the BRCA1-C complex17,18, which stimulates resection synergistically to an even greater extent. A mutation in phosphorylated CtIP (S327A), which disrupts its binding to the BRCT repeats of BRCA1 and hence the integrity of the BRCA1-C complex19-21, inhibits resection, showing that BRCA1-C is a functionally integrated ensemble. Whereas BRCA1-BARD1 stimulates resection in DSB repair, it paradoxically also protects replication forks from unscheduled degradation upon stress, which involves a homologous recombination-independent function of the recombinase RAD51 (refs. 4-6,8). We show that in the presence of RAD51, BRCA1-BARD1 instead inhibits DNA degradation. On the basis of our data, the presence and local concentration of RAD51 might determine the balance between the pronuclease and the DNA protection functions of BRCA1-BARD1 in various physiological contexts., The Swiss National Science Foundation (grant nos. 310030_207588 and 310030_205199) and the European Research Council (grant no. 101018257) support the research in the Cejka laboratory. M.R.D.S. is a recipient of the EMBO Postdoctoral Fellowship (grant no. ALTF-710-2021). Work in the Huertas laboratory was supported by grant no. PID2022-136791NB-I00 funded by grant no. MICIU/AEI/10.13039/501100011033/FEDER/UE. This work is supported by Agence Nationale de la Recherche (grant no. ANR-21-CE44-0009) and by IDRIS (grant no. AD010314343R1) to R.G. Research in the Noordermeer laboratory is funded by the European Union through the MSCA doctoral network Replifate and by Oncode Institute. We thank the Sung laboratory for communicating data before publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection [Dataset]

  • Ceppi, Ilaria
  • Dello Stritto, Maria Rosaria
  • Mütze, Martin
  • Braunshier, Stefan
  • Mengoli, Valentina
  • Reginato, Giordano
  • Võ, Hồ Mỹ Phúc
  • Jimeno, Sonia
  • Acharya, Ananya
  • Roy, Megha
  • Sanchez, Aurore
  • Halder, Swagata
  • Howard, Sean Michael
  • Guérois, Raphaël
  • Huertas Sánchez, Pablo
  • Noordermeer, Sylvie M
  • Seidel, Ralf
  • Cejka, Petr
Methods: In the uploaded files, we present mass photomether and single-molecule magnetic tweezer data from the main and extended data figures. The uploaded files include all the information required to plot the graphs as indicated in the attached main and extended data figures. Mass photometry measurements were performed on a TwoMP mass photometer (Refeyn Ltd). First, borosilicate microscope glass plate (No. 1.5 H thickness, 24 x 50 mm, VWR) were cleaned by sequential soaking in Milli-Q-water, isopropanol and Milli-Q-water followed by drying under a stream of clean nitrogen. Next, silicone gaskets (CultureWell Reusable Gasket, Grace Bio-Labs) were placed on the clean coverslip to create a defined well for sample delivery. To convert optical reflection-interference contrast into a molecular mass, a known protein size marker (NativeMark Unstained Protein Standard, Invitrogen) was measured on the same day. For mass measurements, gaskets were filled with 18 ml measurement buffer (25 mM Tris-HCl pH 7.5, 1 mM ATP, 3 mM magnesium acetate) to allow focusing the microscope onto the coverslip surface. Subsequently, 40 nM of either BRCA1 or BRCA1-BARD1 were added into the well (final volume, 20 ml) and sample binding to the coverslip surface was monitored for 1 min using the software AcquireMP (Refeyn Ltd). Data analysis was performed using DiscoverMP software (Refeyn Ltd). Single-molecule magnetic tweezer experiments were carried out in a custom-built magnetic tweezers setup. The DNA constructs were linked at their biotinylated ends with streptavidin-coated magnetic beads (Dynabeads M280 [Thermo Fischer Scientific]) and flushed into the flow cell, where the bottom slide was coated with antidigoxigenin to ensure specific surface binding. Moving the magnet closer to the flow cell resulted in the stretching of the DNA molecules that were attached to a magnetic bead. Tracking of the magnetic beads for all measurements was conducted at 300 Hz using video microscopy and real-time GPU-accelerated image analysis. The magnetic forces were calibrated based on fluctuation analysis. The measurements were performed in a reaction buffer (25 mM Tris-acetate pH 7.5, 2 mM magnesium acetate, 1 mM ATP, 1 mM DTT, 0.1 mg/ml BSA), with the indicated protein concentrations at a temperature of 37°C and forces between 15-25 pN. The analysis of the recorded traces was conducted with a custom written MATLAB program. We considered only traces from measurements where the magnetic bead position was traceable for at least 300 s. The acquired processivity and velocity for the unwinding events were calculated by fitting linear segments to parts of the recorded traces with approximately constant velocity, which were used to construct the histograms and for statistical analysis. To quantify the ratio of rewinding/unwinding events, the total number of the two events, acquired as described above, was determined for a fixed period of 300 sec for each recorded trace. To characterize the different protein combinations and WRN variants, the difference between the maximum value and the minimum value of DNA extension for a given molecule was calculated during the first 300 sec and expressed as ΔDNA-length. Each dot represents one measured molecule. All Data were named according to how they appear in the results section. Main Fig. 2b,c, Extended Data Fig. 2f-h, Extended Data Fig. 3j, Extended Data Fig 7d are single-molecule magnetic tweezer data. Extended Data Fig. 1a are Mass photometry data., DNA double-strand break (DSB) repair by homologous recombination (HR) is initiated by DNA end resection, a process involving the controlled degradation of the 5'-terminated strands at DSB sites. The breast cancer suppressor BRCA1-BARD1 not only promotes resection and HR, but it also protects DNA upon replication stress. BRCA1-BARD1 counteracts the anti-resection and pro-non-homologous end-joining factor 53BP1, but whether it functions in resection directly has been unclear. Using purified recombinant proteins, we show here that BRCA1-BARD1 directly promotes long-range DNA end resection pathways catalyzed by the EXO1 or DNA2 nucleases. In the DNA2-dependent pathway, BRCA1-BARD1 stimulates DNA unwinding by the WRN/BLM helicase. Together with MRE11-RAD50-NBS1 (MRN) and phosphorylated CtIP, BRCA1-BARD1 forms the BRCA1-C complex, which stimulates resection synergistically to an even greater extent. A mutation in phosphorylated CtIP (S327A), which disrupts its binding to the BRCT repeats of BRCA1 and hence the integrity of the BRCA1-C complex, inhibits resection, showing that BRCA1-C is a functionally integrated ensemble. While BRCA1-BARD1 stimulates resection in DSB repair, it paradoxically also protects replication forks from unscheduled degradation upon stress, which involves an HR-independent function of the recombinase RAD51. We show that in the presence of RAD51, BRCA1-BARD1 instead inhibits DNA degradation. Based on our data, the presence and local concentration of RAD51 might determine the balance between the pro-nuclease and the DNA protection functions of BRCA1-BARD1 in various physiological contexts., Swiss National Science Foundation: 310030_207588 Swiss National Science Foundation: 310030_205199 European Research Council: Grant 101018257 European Molecular Biology Organization: ALTF-710-2021 European Union: PID2022-136791NB-I00, MICIU/AEI/10.13039/501100011033/FEDER/UE Agence Nationale de la Recherche: ANR-21-CE44-0009 IDRIS: AD010314343R1 European Union, MSCA doctoral network Replifate and by Oncode Institute, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence

  • Flores, Natalia García
  • Fernández-Aroca, Diego M.
  • Garnés-García, Cristina
  • Domínguez-Calvo, Andrés
  • Jiménez-Suárez, Jaime
  • Sabater, Sebastià
  • Fernández-Aroca, Pablo
  • Andrés, Ignacio
  • Cimas, Francisco J.
  • de Cárcer, Guillermo
  • Belandia, Borja
  • Palmero, Ignacio
  • Huertas, Pablo
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
Pan-cyclin-dependent-kinase (CDK) inhibitors are a new class of targeted therapies that can act on multiple CDKs, with dinaciclib being one of the most promising compounds. Although used as a monotherapy, an interesting approach could be to combine it with radiotherapy. Here, we show that dinaciclib increases radiosensitivity in some experimental models of lung and colon cancer (A549 or HCT 116) but not in others (H1299 or HT-29). Dinaciclib did not alter serine-protein kinase ATM signalling or cell cycle profiling after ionising-radiation exposure, which have been described for other CDK inhibitors. Interestingly, in terms of apoptosis, although the combination renders a clear increase, no potentiation of the ionising-radiation-induced apoptosis was observed. Mechanistically, inhibition of CDK12 by dinaciclib diminishes BRCA1 expression, which decreases homologous recombination (HR) and probably promotes the nonhomologous end joining repair process (NHEJ), which ultimately promotes the induction of ionising-radiation-associated cellular senescence in a TP53-dependent manner, explaining the lack of effect observed in some experimental models. In conclusion, our report proposes a molecular mechanism, based on the signalling axis CDK12-BRCA1, involved in this newly identified therapeutic effect of dinaciclib, although other players implicated in HR should not be discarded. In addition, our data provide a rationale for more selective and personalised chemo/radiotherapy treatment according to the genetic background of the tumour., We appreciate the technical assistance of SIB at IB, core facilities of IIB and the staff from the Radiotherapy Unit at the General Universitary Hospital of Albacete This work has been supported by grant PID2021-122222OB-I00 and PID2021-122600OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by Europena Regional Development Fund (FEDER) A way to make Europe and grant to RS-P and IP. S2022/BMD-7393 funded by Regional Government of Madrid to IP. PH lab is funded by grant PID2022-136791NB-I00 from MICIU/AEI/10.13039/501100011033/FEDER/UE. RS-P is also funded by UCLM with grant 2022-GRIN-34150 and by Agencia de Investigación e Innovación, Junta de Comunidades de Castilla-La Mancha grant SBPLY/23/180225/000007. FJC is funded by contracts for postdoctoral researchers for scientific excellence in the development of the Plan Propio I + D + i, co-financed by the European Social Fund Plus (ESF+). NGF is funded by ‘Investigo Programme’, for hiring young job seekers to carry out research and innovation initiatives, within the framework of the Recovery, Transformation and Resilience Plan – financed by the European Union – Next Generation EU, called by Order 190/2021, of 22 December, of the Regional Ministry of Economy, Business and Employment of the Regional Government of Castilla-La Mancha. JJ-S is funded by ‘Contrato predoctoral para la formación de personal investigador en el marco del plan propio de I + D + I UCLM 2020-PREDUCLM-15144’, co-financed by the European Social Fund Plus (ESF+). AD-C is funded with FPU fellowships from the Ministerio de Educación, Formación Profesional y Deportes (Lpb23). We are grateful for the funds contributed by Fundacion Leticia Castillejo and by the participants in the crowdfunding project ‘Irradiando Esperanza’, in particular to: Taller Solidario Árbol De La Vida (Las Pedroñeras), Asociación Comarcal Contra El Cáncer De Motilla Del Palancar, asociación Jareña Contra el Cancer Junta local contra el cáncer de Casimarro, and ACEPAIN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models

  • Camarillo, Rosa
  • Prados-Carvajal, Rosario
  • Cruz-García, Andrés
  • Rodríguez-Real, Guillermo
  • Herencia-Ropero, Andrea
  • Serra, Violeta
  • Jimeno, Sonia
  • Huertas Sánchez, Pablo
DNA end resection is a critical step that governs how a broken chromosome will be repaired. As such, it is heavily regulated by multiple cellular signals and processes. Alterations in the regulation of DNA end resection have consequences for cell survival upon exposure to cytotoxic agents, including those used during cancer chemotherapy. Here, we identified several small molecules that affect the process of DNA end resection. Among them, we focus on determining the mode of action of merbarone, a DNA topoisomerase II inhibitor. We uncover a role of the topoisomerase IIβ isoform in the full processing of DNA breaks. Moreover, we show that the effect of merbarone is affected by the formation of G4 quadruplexes and that BRCA1-deficient cancer cells are sensitive to merbarone. Strikingly, this sensitivity can be partially suppressed in cell lines expressing hypomorphic versions of BRCA1 lacking exon 11, a hypomorph that has been linked to PARPi-resistance. Using cellular models, we show that PARPi- and merbarone-resistant BRCA1 exon 11 mutant cells, but not wildtype BRCA1 cells, are sensitive to the combination of both drugs. Finally, we show that combination of merbarone and the PARPi olaparib has a mild antitumor effect in a PARPi-resistant PDX model bearing a BRCA1 exon 11 mutation., This work was funded by the R+D+I grants SAF2013-43255-P, SAF2016-74855-P, PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE to P.H., and grants PID2022-140603NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE and the Ideas Semilla Project IDEAS222767JIME from the Asociación Española Contra el Cáncer (AECC) to S.J and the SINERGIA project SNRGS247052PRAD from AECC to RP-C. RC-D was funded with an FPI fellowship from the Spanish Ministry of Economy and Competitivity. RP-C was funded with an FPU fellowship from the Spanish Ministry of Education and a Postdoctoral Fellowship from the Asociación Española Contra el Cáncer (AECC). AC-G was supported by the Government of Mexico with a fellowship of the CONACYT. CABIMER is supported by the Regional Government of Andalucía (Junta de Andalucía). V.S. received funds from the Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (PI20/00892 and CPII19/00033). AH-R received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). P. Huertas and R. Prados-Carvajal disclose non-financial support from AstraZeneca. Additionally, V. Serra reports research grants from AstraZeneca and personal fees and/or nonfinancial support from AstraZeneca and GSK., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circadian regulation of homologous recombination by cryptochrome1-mediated dampening of DNA end resection

  • Romero-Franco, Amador
  • Checa-Rodríguez, Cintia
  • Jimeno, Sonia
  • Castellano-Pozo, Maikel
  • Aguilera, Paula
  • Miras, Héctor
  • Wals-Zurita, Amadeo
  • Jimeno-González, Silvia
  • López-Contreras, Andrés J.
  • Huertas, Pablo
[Data availability] All relevant data are included in the manuscript.Source data are provided with this paper. ChIP-seq data are deposited at GEO under the accession number GSE261427. All data is available from the authors upon request. Source data are provided with this paper., Genomic stability maintenance requires the repair of DNA breaks in the most accurate fashion. So, an exquisite regulatory network controls the choice between different repair mechanisms to maximize genome integrity. This relies mostly at the level of DNA end resection, the initial steps of the homologous recombination. On the other hand, numerous cellular activities follow a 24 h oscillation known as the circadian cycle. Thus, we explored the regulation of the choice between different DNA break repair pathways along the circadian cycle. Here we show that in human cells DNA resection shows a circadian oscillation, with a peak at early morning followed by a partial and progressive reduction until late afternoon. Such regulation depends on the circadian clock core component CRY1, which modulates the anti-resection activity of CCAR2 to limit CtIP at nightfall. Additionally, such regulation requires DNA-PK-mediated phosphorylation of CRY1. Finally, this circadian regulation impacts cancer progression and response to radiation therapy of specific tumours., This work was funded by the R + D + I grants PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE, the grant P18-RT-1204 from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía and the grant PRYGN246626HUER from the Asociación Española Contra el Cáncer. The mouse work in the ALC laboratory was funded by the R+D+I grant PID2020-119329RB-I00, the SJ lab is funded by the grant PID2022-140603NB-I00, and the SJG lab is funded by the grant PID2022-139253N, all three funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE. MC-P is the recipient of an MSCA-IF-2020 (coDNAres) that covers his salary and part of the reagents. AR-F is funded with a FPU fellowship from the Spanish Ministry of Education and PA was supported by a postdoctoral fellowship from the Junta de Andalucía and the European Social Fund (202099908313486), and by a postdoctoral grant from the Scientific Foundation of the Spanish Association Against Cancer (POSTD234422AGUI). CABIMER is supported by the regional government of Andalucía (Junta de Andalucía). We thank José Carlos Reyes-Rosa for the critical reading of the manuscript. We also want to thank the Microscopy and Genomic Unit of CABIMER for their support in the experiments., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NK-A 17E-233I: a novel competitive inhibitor of human dihydroorotate dehydrogenase (DHODH) for cancer therapy

  • Anwar, Mohammed Moustapha
  • Meseguer, Salvador
  • García-Rodríguez, Néstor
  • Krupinska, Ewa
  • Sele, Céleste
  • Rodríguez-Jiménez, Aida
  • Verma, Suraj
  • Sagadevan, Samna
  • Ramon, Javier
  • Martí, Ramon
  • Occhipinti, Annalisa
  • Angione, Claudio
  • Ordóñez-Morán, Paloma
  • Knecht, Wolfgang
  • Huertas Sánchez, Pablo
  • Juanes, M. Ángeles
Human dihydroorotate dehydrogenase (DHODH) is the rate-limiting enzyme in pyrimidine de novo synthesis and represents a promising target for cancer therapy. However, current inhibitors of DHODH have limited clinical effectiveness and adverse effects. Herein, we report NK-A 17E-233I, a novel small-molecule inhibitor of the human DHODH enzyme, identified through a prospective virtual screening methodology. Molecular docking and biochemical assays show NK-A 17E-233I functions as a pure or partial competitive inhibitor with respect to the natural substrate, dihydroorotate (DHO). It adopts a distinct binding mode from classical inhibitors that target the flavin mononucleotide (FMN) binding cavity of the hydrophobic tunnel. NK-A 17E-233I exhibits selective cytotoxicity in both human cancer cell lines and patient-derived intestinal organoids, inducing DNA damage, S-phase arrest, and cell death. Unlike Brequinar, NK-A 17E-233I preserves mitochondrial respiration via complexes I and II and maintains ATP-linked basal respiration, avoiding the impairment of the electron transport chain (ETC). Our findings imply the aptitude of NK-A 17E-233I as a novel competitive inhibitor of human DHODH, representing a significant advancement in this field since the 1990s., This work was supported by a grant [Plan GenT, CIDEGENT/2021/026] from the CIDEGENT Excellent Research Program of the Valencian regional government, grants [CNS2024-154649 and PID2022-140899NB-I00] awarded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by “ERDF/EU” awarded to MAJ (Juanes Lab). Part of the equipment employed in the current work was funded by Generalitat Valenciana and cofinanced with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). A fellowship from "the Generalitat Valenciana, Conselleria de Sanitat—Acciones en materia de recursos humanos para impulsar la investigación y la formación en investigación sanitaria, biomédica y de salud pública para el ejercicio 2024," was awarded to MMA (Juanes Lab). This work was also supported by a grant [PID2022-136791NB-I00] project awarded by MCIN/AEI/https://doi.org/10.13039/501100011033 to PH, EMERGIA 2021 program from the Andalusian Regional Government-Junta de Andalucía (EMC21_00057) to NG-R, and PI21/00554 from the Instituto de Salud Carlos III (cofunded with ERDF) and 202020–30-31 from the Fundació la Marató de TV3 to RM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biodegradable polyacrylamide-based hydrogels with unique bactericidal and osteoinductive properties to improve the clinical success of porous titanium implants

  • Martínez, Guillermo
  • Castellano-Pozo, Maikel
  • Merinero de los Santos, Manuel
  • Casado-Jurado, David
  • Huertas Sánchez, Pablo
  • Pajuelo, Eloísa
  • De-Miguel, Manuel
  • Begines, Belén
  • Torres, Yadir
  • Alcudia, Ana
Stress-shielding phenomenon, infections, and limited bone integration are traditional drawbacks associated with titanium implants. Biodegradable polyacrylamide-based hydrogels synthesized with an 8-fold scaled up, disulfide bond-containing crosslinker, were prepared to overcome these limitations. Hydrogels' biodegradability in the presence of glutathione has been demonstrated. Additionally, hydrogels exhibited strong antibacterial activity against pathogens such as P. aeruginosa and S. aureus, along with promising osseointegrative properties, in vitro fibroblast (CCL-1) viability, and in vivo biocompatibility in C. elegans. Porous titanium (Ti) fabricated via space-holder technique were infiltrated with previously described hydrogels. The optimal system, featuring a 4 wt% crosslinked acrylamide-based hydrogel infiltrated into 60 vol%, 355–500 μm Ti substrate, showed excellent biomechanical integrity and biofunctionality, supporting its potential as a safe and effective bone implant. Additionally, the study introduces streamlined, cost-effective methodologies for implant testing and characterization., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Grant Numbers, PID2022-137911OB-I00 and PID2022-136791NB-I00. Escherichia coli expressing GFP and Pseudomonas putida expressing mScarlet, respectively, and Eduardo Villalobo for his assistance with the manipulation of these two bacterial strains. The authors also thank Biblioteca and Servicios Generales from Universidad de Sevilla and especially Servicio de RMN for facilities, and and VII Plan Propio de Investigación y Transferencia-US 2022 for Grant Numbers 2022/00000332 and 2022/00000277. G.M.M. thanks VII Plan Propio de Investigación from University of Seville for predoctoral Grant, M.C.P. thanks to Marie Sklodowska-Curie Actions for MSCA IF grant coDNAres 101023902, and D.C. thanks Ministerio de Educación y Formación Profesional for a grant ``Beca de Colaboración de Estudiantes en Departamentos Universitarios´´., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

miRNA-mediated cell-to-cell communications boost DNA repair during the radioadaptive response

  • Domínguez-Pérez, M. Carmen
  • Fernández-Ávila, María Jesús
  • González-Vinceiro, Lourdes
  • Zannini, Laura
  • Peinado, Héctor
  • González-Prieto, Román
  • García-Rodríguez, Néstor
  • Huertas Sánchez, Pablo
The radioadaptive response (RAR) is a phenomenon in which a low, or priming, dose of ionizing radiation enhances cellular resistance to subsequent higher doses. We investigated whether RAR involves alterations in homologous recombination (HR), a high-fidelity DNA repair pathway. Using fibroblast models, we found that primed cells exhibit accelerated DNA end resection, an initial and essential HR step. This effect is mostly mediated by a bystander mechanism involving small extracellular vesicles (sEVs), as conditioned media fully replicated it. RNA profiling of sEVs identified miR-126-3p and miR-451a as key regulators of this response. Significantly, inhibiting miR-451a induced RAR in normally unresponsive cells. We further identified a miR-451a-p38-CCAR2 axis that promotes HR through suppression of CCAR2. Our findings delineate a novel microRNA-mediated, sEV-driven mechanism that regulates HR during RAR, with potential therapeutic implications., This work was funded by the R + D + I grant PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE. McD-P is funded with a FPI fellowship number PRE2020-091834. NG-R is funded by the EMERGIA 2021 program from the Junta de Andalucía (EMC21_00057). CABIMER is supported by the regional government of Andalucía (Junta de Andalucía). We also want to thank the Microscopy and Genomic Unit of CABIMER for their support in the experiments and Iván V. Rosado for critical reading of the manuscript. Funding to pay the Open Access publication charges for this article was provided by an agreement between the University of Seville and Oxford University Press., Peer reviewed